Meglumine Antimoniate

Scabicide & Pediculocide · Leishmaniacide

Indications

Treatment of visceral leishmaniasis (Kala-azar) or cutaneous leishmaniasis (except resistant Leishmaniasis aethiopica).

Dosage

Visceral Leishmaniasis: Adults: IM injection of 20 mg/kg per day (i.e. 75 mg/kg per day of meglumine antimony) without exceeding 850 mg, for 20 consecutive days. Treatment must be continued until the disappearance of parasites from splenic needle aspirates obtained at 14 days intervals. Cutaneous leishmaniasis: With the exception of forms due to L Braziliensis and L. Amazonensis: Lesions should be envisaged only at the early stage. Adults: Local treatment: Injection of 1 to 3 mL at the base of the lesion, repeated once (or twice if no apparent result is obtained) at 1 or 2 day intervals. Systemic treatment: IM injection of 10 to 20 mg/kg per day, (i.e., 37 to 75 mg/kg per day of meglumine antimony) until clinical cure or disappearance of parasites from dermal liquid collected by scarification, then for a few extra days. Cutaneous leishmaniasis of L. Braziliensis and L. Amazonensis:…

Adverse Effects

Transient febrile reaction accompanied by chills or sensation of faintness with sweating, cough and vomiting may occur at the start of treatment. Headache, general malaise, difficult and uneasy breathing, skin rash, facial oedema, abdominal pain, impaired liver and kidney function have rarely been reported. Very rare cases of pancreatitis have been observed.

Risk Factor (Pregnancy/Lactation)

Precautions: Possible iron or other deficiencies must be corrected before starting treatment. A high protein content diet should also be followed during the treatment. Due to the risk of intolerance to antimony, it is advisable to monitor ECG tracing, hepatic and renal function tests throughout the treatment period.

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.